Monalisa Mohanty

Monalisa Mohanty

Auto-generated profile, based on publicly available information

Monalisa Mohanty

All India Institute of Medical Sciences - Bhubaneswar, Microbiology, Bhubaneshwar, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Indian Journal of Medical Microbiology
Verified
Journal Article
Closed access
MMMonalisa Mohanty
Monalisa Mohanty
BMBaijayantimala Mishra
Baijayantimala Mishra
ASAmit Kumar Satapathy
Amit Kumar Satapathy
KGKrishna Mohan Gulla
Krishna Mohan Gulla
RDRashmi Ranjan Das
Rashmi Ranjan Das
SPSailendra Panda
Sailendra Panda

8 December 2022 in Cureus
Verified
Journal Article
Open access
MMMonalisa Mohanty
Monalisa Mohanty
BMBaijayantimala Mishra
Baijayantimala Mishra
ASArvind K. Singh
Arvind K. Singh
PMPrasanta Raghab Mohapatra
Prasanta Raghab Mohapatra
KGKavita Gupta
Kavita Gupta
SBSourin Bhuniya
Sourin Bhuniya
The rapidly mutating Omicron SARS-CoV-2 variant has replaced the previous dominant SARS-CoV-2 variants like alpha, and delta resulting in the amplification of coronavirus disease 2019 (COVID-19) cases. The present study was conducted to compare the clinical profile and vaccination status in patients infected with Omicron and non-Omicron SARS-CoV-2 variants. All patients who tested positive for coronavirus disease 2019 (COVID-19) during the study period (January 2022 to February 2022) were further tested for detection of SARS-CoV-2 Omicron variant by using Omisure kit (TATA MD CHECK RT-PCR, TATA MEDICAL AND DIAGNOSTICS LIMITED, Tamil Nadu, INDIA). Clinico-demographic factors and vaccination status were compared between both Omicron and non-Omicron groups. A total of 1,722 patients who tested positive for COVID-19 were included in the study, of which 656 (38.1%) were Omicron and 1,066 (61.9%) were non-Omicron SARS-CoV-2 variants. Blood group and vaccination status were the major predictors for Omicron. The proportion of male patients was 58.4% in the Omicron group and 57.9% in the non-Omicron group. Maximum cases (86.2%) belonged to >18-60 years age group, 7.3% to >60 years age group, and least to 0-18 years (6.5%). The average age of the study participants was 35.4 ± 14.5 years. Vaccinated participants had less chance of having Omicron than the unvaccinated participants (p-value - 0.003). Fever and loss of smell were found to be significantly associated with the non-Omicron SARS-CoV-2 variant. (p-value < 0.05). The present study reflects that the clinical course of the disease is milder in Omicron as compared to the non-Omicron variant. However rapid rise in cases can badly affect the healthcare system demanding good preparedness to tackle all the predicaments. Good Vaccination coverage should be of utmost priority irrespective of the variant type.

22 March 2025 in Cureus
Verified
Journal Article
Open access
PDF file
SRSutapa Rath
Sutapa Rath
SFShehnaz Firdaus
Shehnaz Firdaus
GNGayatree Nayak
Gayatree Nayak
MMMonalisa Mohanty
Monalisa Mohanty
GJGayatree Nayak Jr.
Gayatree Nayak Jr.
Nontuberculous mycobacteria (NTM), otherwise known as atypical mycobacteria, primarily cause pulmonary disease. However, with the increase in the immunocompromised population, infections caused by NTM at extrapulmonary (EP) sites have been on the rise in the past decade. Clinical presentations can commonly include lymphadenitis and skin and soft tissue infections. The diagnosis is challenging due to the invasive nature of the sample collection and the low degree of suspicion. Furthermore, detection up to the speciation level is important as management is species-specific. With limited data and studies regarding extrapulmonary nontuberculous mycobacteria (EP-NTM) disease, a multidisciplinary approach with awareness is required to recognize the pathogen early for appropriate and timely institution of therapy.

15 May 2024 in Indian Journal of Medical Microbiology
Verified
Journal Article
Closed access
PMPrabhudutta Mamidi
Prabhudutta Mamidi
SPSailendra Panda
Sailendra Panda
ARAmrita Ray
Amrita Ray
MMMonalisa Mohanty
Monalisa Mohanty
MMMadhab Charan Mandal
Madhab Charan Mandal
BMBaijayantimala Mishra
Baijayantimala Mishra

14 September 2022 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
MMMonalisa Mohanty
Monalisa Mohanty
BMBaijayantimala Mishra
Baijayantimala Mishra
CSChandra Sekhar Sirka
Chandra Sekhar Sirka
PMPrasanta Raghab Mohapatra
Prasanta Raghab Mohapatra
: Mycobacterium abscessus complex is a group of nontuberculous mycobacteria (NTM). The NTM may involve skin, soft tissue, and other organs like the eye and central nervous system. Clinically may mimic multidrug resistance. Here, we present a case of a 29‐year man with a history of multiple scalp swellings with mild symptoms. He had undergone multiple triamcinolone acetonide injections on his scalp to stop hair fall and baldness 2 months prior. As there was a history of injections on the scalp and lesions associated with minimal symptoms, we suspected the possibility of NTM and fungal infections. As a part of treatment and obtaining a sample for investigation, lesions were aspirated with a needle. The swellings contained gelatinous material, which was sent for microscopic examination, and revealed the presence of acid‐fast bacilli (AFB). Xpert MTB/RIF assay was negative for mycobacteria (MTB complex), but culture revealed NTM was identified as M. abscessus complex by line probe assay. Based on the diagnosis, the patient was treated with an injection of amikacin, moxifloxacin, and azithromycin. The lesions improved. The patient has completed over a year of follow-up with no recurrence noted. Mycobacterium abscessus, a rapidly growing NTM, has been occasionally reported to cause cutaneous soft tissue infection when injected with nonsterile medicine or needles. Therefore, a high index of suspicion for NTM infection is warranted in patients with cutaneous scalp abscess following scalp injections for hair loss.

23 March 2024 in Future Virology
Verified
Journal Article
Closed access
PMPrabhudutta Mamidi
Prabhudutta Mamidi
BMBaijayantimala Mishra
Baijayantimala Mishra
SPSailendra Panda
Sailendra Panda
ARAmrita Ray
Amrita Ray
DJDeepak Jena
Deepak Jena
KGKavita Gupta
Kavita Gupta